期刊文献+

血液相关指标与弥漫大B细胞淋巴瘤预后关系分析 被引量:3

A Prognosis Analysis of Blood-related Indicator with Diffuse Large B Cell Lymphoma
下载PDF
导出
摘要 目的分析弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)相关临床资料,探讨常见血液相关指标对DLBCL预后的指导意义。方法回顾性分析2011年1月至2017年12月世纪坛医院收治的45例初治DLBCL患者临床资料,生存分析应用Kaplan-Meier法,单因素分析应用Log-rank检验,多因素分析应用Cox回归模型。结果单因素分析结果显示:血小板计数(PLT)、Hans分型、血红蛋白水平(HGB)、血清白蛋白(ALB)水平差异具有统计学意义(P<0.05),与预后有关。多因素分析结果显示:PLT、Han分型差异具有统计学意义,可作为DLBCL独立预后因素。性别、年龄、初诊原发部位、红细胞计数(RBC)、白细胞计数(WBC)、中性粒细胞绝对值计数(Neu#)、淋巴细胞绝对值计数(Lym#)、中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞绝对值计数比值(PLR)、乳酸脱氢酶(LDH)、总蛋白(TP)差异均无统计学意义。结论PLT≤209×10^9/L,Hans分型为非生发中心型,HGB≤100g/L,ALB<40g/L可能是DLBCL不良预后因素。PLT、Hans分型可作为DLBCL患者总生存期的独立影响因素。 Objective To analyze the clinical characteristics of the patients with diffuse large B-cell lymphoma(DLBCL),and evaluate the significance of blood-related indicators in the prognosis of DLBCL.Methods The clinical data of forty-five patients who were newly diagnosed DLBCL in the Beijing Shijitan Hospital from January,2011 to December,2017 was collected.Kaplan-Meier survival analysis,log-rank test and Cox regression model multivariate analysis were used to analyze the prognostic factors of DLBCL patients.Results Univariate analysis showed that PLT,Hans immunological subtypes,HGB and ALB were significantly related to the prognosis of DLBCL(P<0.05),while gender,age,invasive site of initial diagnosis,RBC,WBC,Neu#,Lym#,NLR,PLR,LDH and TP were not related to the prognosis of DLBCL(P>0.05).Multivariate analysis showed PLT,Hans immunological subtypes were independent prognostic factors of DLBCL(P<0.05).Conclusion PLT≤209×10^9/L,Immuno-phenotype of non-germinal center subtype,HGB≤100g/L and ALB<40g/L are the adverse prognostic factors of prognosis in patients with DLBCL.PLT and Hans immunological subtypes are the independent risk factors of prognosis in DLBCL patients.
作者 赵瑾 赵颖 张曼 ZHAO Jin;ZHAO Ying;ZHANG Man(Clinical Laboratory Medicine,Beijing Shijitan Hospital,Capital Medical University,Clinical Laboratory Medicine,Peking University Ninth School of Clinical Medicine,Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics,Beijing 100038,China)
出处 《标记免疫分析与临床》 CAS 2019年第9期1485-1488,1511,共5页 Labeled Immunoassays and Clinical Medicine
基金 北京市医管局“登峰”人才培养计划(编号:DFL20150701) 尿液细胞分子诊断北京市重点实验室建设经费(编号:2019-JS02)
关键词 弥漫大B细胞淋巴瘤 预后 生存分析 Diffuse large B cell lymphoma Prognosis Survival analysis
  • 相关文献

参考文献6

二级参考文献45

  • 1Harris NL,Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic disease of the hematopoietic and lymph- oid tissues : report of the Clinical Advisory Committee meeting-Air- lie House, Virginia, November 1997. J Clin Oncol, 1999, 17: 3835-3849.
  • 2Chuang SS, Lin CN, Li CY. Malignant lymphoma in southern Tai- wan according to the revised European-American classification of lymphoid neoplasms. Cancer,2000,89 : 1586-1592.
  • 3Cheson BD, Homing S J, Coiffer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin' s lym- phomas. NCI Sponsored International Working Group. J Clin On- col, 1999, 17:1244-1253.
  • 4Harris NL,Jaffe ES,Stein H,et al. A revised European-American classification of lymphoid neoplasms : a proposal from the Interna- tional Lymphoma Study Group. Blood, 1994, 84 : 1361-1392.
  • 5Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer. 2001.
  • 6Lerner RE, Thomas W, Defor TE, et al. The International Prog- nostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin' s lymphoma in second complete or partial remission. Biol Blood Marrow Trans- plant, 2007, 13 : 486-492.
  • 7Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with dif- fuse large-B-cell lymphoma. N Engl J Med, 2002, 346 : 235-242.
  • 8Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera Inter- national Trial(MinT)Group. Lancet Oncol, 2006, 7: 379-391.
  • 9Pfreundschuh M, Kloess M, Zeynalova S, et al. Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL) : results of the completed RICOVER-60 trial of the German High-Grade Non- Hodgkin' s Lymphoma Study Group (DSHNHL). Blood, 2006, 108, 205.
  • 10Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101: 78 -84.

共引文献262

同被引文献41

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部